Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567804 | 0.95 | CFTR (0.51) | CFTRGAAMRGPRX4AKR1C3AKR1C2 | |
| SCHEMBL6566893 | 0.91 | IDO1 (0.48) | CFTRGAAMRGPRX4ACP3IDO1 | |
| SCHEMBL6564379 | 0.91 | CFTR (0.47) | CFTRCASRGAAMRGPRX4AKR1C3 | |
| SCHEMBL6566526 | 0.91 | CFTR (0.43) | CFTRCASRGAAMRGPRX4IDO1 | |
| SCHEMBL6566067 | 0.90 | CFTR (0.46) | CFTRGAAMRGPRX4SLC6A9CNR2 | |
| SCHEMBL6565797 | 0.90 | CFTR (0.42) | CFTRCASRGAAMRGPRX4PTGS1 | |
| SCHEMBL6564533 | 0.89 | GAA (0.48) | CFTRGAAPPARA | |
| SCHEMBL6566099 | 0.89 | CFTR (0.43) | CFTRCASRGAAMRGPRX4IDO1 | |
| SCHEMBL6567751 | 0.88 | CFTR (0.42) | CFTRGAAMRGPRX4HTT | |
| SCHEMBL6567957 | 0.88 | CFTR (0.48) | CFTRGAAMRGPRX4IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | CFTR 865/4885CASR 1621/4885GAA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.